

ASCIA 2019 CONFERENCE

PROGRAM BOOK

**30TH ANNUAL CONFERENCE OF THE AUSTRALASIAN SOCIETY OF
CLINICAL IMMUNOLOGY AND ALLERGY (ASCIA)**

3-7 September 2019 | Perth Convention and Exhibition Centre
Perth | Western Australia

ASCIA is the peak professional body of clinical immunology and allergy specialists
in Australia and New Zealand

ASCIA is a member society of the Asia Pacific Association of Allergy, Asthma and
Clinical Immunology (APAAACI) and the World Allergy Organisation (WAO)

ASCIA acknowledges artist Valerie Sparks for use of her artwork 'Emergent' 2015
for our identifier, marketing and promotional materials


ascia

australasian society of clinical immunology and allergy

www.ascia2019.com

SPONSORS

ASCIA gratefully acknowledges the generous support of the following sponsors:

Diamond sponsors



Platinum sponsors



Gold sponsors



Sponsors and Exhibitors

Abacus dx	Ego Pharmaceuticals	National Asthma Council
Abbott	ENT Technologies	National Blood Authority
Allergend	Ferrer Pharma	NeilMed Pharmaceuticals
Allergy & Anaphylaxis Australia	Gamma Allergy	Nestlé
Allergy New Zealand	Grifols	Novartis
AMSL Allergy/NZMSL	GSK	Nutricia
ARRC	HAE Australasia	RACP
AusEE	IDFA	Sanofi
AusPIPS	IDFNZ	Seqirus
Bayer	JMF Centre for PID Melbourne	Stallergenes Greer
Care Pharma	LTR Medical	Takeda
CFAR	MedicAlert Foundation	TAMS
CSL Behring	Mylan	
DBV Technologies	National Allergy Strategy	

Note: The ASCIA 2019 conference program is not influenced by its sponsors or exhibitors

WELCOME

CONTENTS

Sponsors	1
Sponsors and Exhibitors	1
Welcome	2
Information (A-Z)	3
Exhibition Floorplan	5
Exhibitors	6
App	7
Program Summary	9
CFAR Symposium Program	11
CFAR Symposium Hot Publications	12
Conference Day 1 Program (Wednesday)	13
Conference Day 2 Program (Thursday)	14
Conference Day 3 Program (Friday)	15
ASCIA Clinical Grand Rounds Presentations	16
ASCIA Dietitians Day Program	17
ASCIA Nurses Day Program	18
ASCIA Associate Medical Sessions Program	19
ASCIA Immunopathology Day Program	20
International Speakers	21
Basten Orator	24
Speakers and Chairs Index	25
ASCIA Clinical Research Presentations	28

It is a pleasure to welcome you to the ASCIA 2019 conference in Perth, Western Australia, the 30th annual conference of the Australasian Society of Clinical Immunology and Allergy (ASCIA).

ASCIA annual conferences provide an international standard of continuing professional development. They are also a unique opportunity to interact and collaborate with colleagues. ASCIA conferences are therefore a highlight of the year for ASCIA members and other health professionals working in allergy, clinical immunology and immunopathology.

The ASCIA 2019 conference program includes presentations by the following international keynote speakers:

- Professor Mark Boguniewicz
- Professor Mariana Castells
- Professor Timothy Craig
- Professor Evan Dellon
- Professor Philippe Eigenmann
- Dr Tomaz Garcez
- Associate Professor Matthew Greenhawt
- Professor Peter Hellings
- Professor Hugh Sampson
- Assistant Professor Carina Venter

The conference includes concurrent sessions for nurses, dietitians and associate (medical) ASCIA members. The following events are also being held in conjunction with the ASCIA 2019 Conference:

- Centre for Food and Allergy Research (CFAR) Symposium 2019 on Tuesday 3 September
- ASCIA WA Immunopathology Day on Saturday 7 September
- ASCIA DAA Centre for Advanced Learning Dietitians Course on Friday 6 and Saturday 7 September <https://daa.asn.au/member-community/blog/centre-for-advanced-learning/food-allergy-and-intolerance/>
- ANZAAG Symposium on Saturday 7 September www.anzaag.com/Events.aspx

We hope you have planned time to see our remarkable state of Western Australia. For inspiration visit www.westernaustralia.com/au/

We look forward to seeing you at the conference.

Kind Regards,

Clinical Prof Michaela Lucas
Chair, ASCIA 2019 Conference

Dr Brynn Wainstein
ASCIA President

Jill Smith
ASCIA CEO

Organising Committee:
Dr Chris Bundell, Rachael Dunn, A/Prof Mina John, A/Prof Richard Loh, Prof Dominic Mallon, Dr Tracy Markus, Dr Patricia Martinez, Dr Andrew McLean-Tooke, Valerie Noble, Dr Richard Nolan, Ingrid Roche, Sandra Vale.

Abstracts

Over 120 abstracts have been submitted which will be presented as:

- ASCIA 2019 posters (displayed from Wednesday 4 to Friday 6 September 2019).
- ASCIA 2019 clinical grand rounds oral presentations (by advanced trainees).
- ASCIA 2019 clinical research oral presentations.

Accepted abstracts are published in the Internal Medicine Journal (online) and these can be accessed on the ASCIA website by the end of September 2019: www.allergy.org.au/conferences/ascia-annual-conference/published-abstracts-ascia

Abstracts were also received for the CFAR Symposium short oral "hot publication" presentations, for food allergy research that has been recently published, or accepted for publication in a peer-reviewed journal. These will be presented as part of the CFAR Symposium on Tuesday 3 September 2019.

App

To improve your meeting experience, ASCIA is pleased to partner with a content publishing platform, myINTERACT, to provide delegates with an ASCIA 2019 Conference App. This includes access to:

- Ask questions and participate in polling using your mobile device during interactive sessions.
- Interactive conference program, with ability to create a personalised schedule and record notes digitally.
- Searchable abstract and poster library which eliminates the need to take photos during poster sessions.
- Provide feedback on each session.
- Notifications of session changes.
- Biographies of international speakers.

Prior to the conference, all delegates will receive an email invitation from myINTERACT to connect to the app. Prior download is encouraged to ensure convenient access to all the information you may need at the conference.

Attendance Certificates

A certificate of attendance is provided to each delegate and is included in the registration envelope, together with a receipt for the registration payment.

Awards and Travel Grants

During the conference a limited number of travel grants are awarded to delegates (advanced trainees, dietitians, nurses, students) who reside outside of the region and have submitted an abstract.

Awards of \$1,000 each for selected posters and case presentations will be presented at the end of the conference. These will be listed on the ASCIA website: www.allergy.org.au/hp/awards-grants/ascia-award-grant-scholarship-recipient

Awards will be announced at the ASCIA 2019 Conference closing function.

Breakfast Sessions

ASCIA 2019 National Allergy Strategy update

Wednesday 4 September 2019, 07.45-08.45
Breakfast will be available from 07.30-07.45
Perth Convention and Exhibition Centre
Supported by the National Allergy Strategy

ASCIA 2019 JSTC forum for supervisors and advanced trainees

Thursday 5 September 2019, 07.45-08.45
Breakfast will be available from 07.30-07.45
Perth Convention and Exhibition Centre
Supported by ASCIA

ASCIA 2019 Primary Immunodeficiency cases

Friday 6 September 2019, 07.45-08.45
Breakfast will be available from 07.30-07.45
Perth Convention and Exhibition Centre
Supported by CSL Behring and JMF Centre for PID Melbourne

Disclaimers

In the event of industrial disruption or a natural disaster the meeting organisers cannot be held responsible for any losses incurred by delegates. The program is correct at the time of printing. However, the organisers reserve the right to alter the program if necessary.

Dress Code

The dress code is smart casual throughout the conference, and cocktail for the Gala Dinner.

Exhibition

The exhibition for the ASCIA 2019 conference will run for three days, from Wednesday 4 to Friday 6 September 2019. All lunches and tea breaks will be served in the exhibition area. There is no exhibition on Tuesday 3 September and there is a limited exhibition on the Saturday 7 September.

Delegates are encouraged to visit the ASCIA 2019 exhibition stands throughout the conference.

Registration

Registration, abstract submission, website:

www.ascia2019.com/registration.php
registration@ascia2019.com
abstracts@ascia2019.com



Sponsorship, exhibition, program

info@allergy.org.au



Smoke Free Policy

The ASCIA 2019 conference is a smoke-free event, including all related social functions.

Social Program

ASCIA 2019 Welcome Function

Wednesday 4 September, 16.30-18.00
Bellevue Ballroom Foyer
Perth Convention and Exhibition Centre

ASCIA 2019 Trainee and Supervisors Dinner Meeting

Wednesday 4 September, 18.30-21.30
Perth Convention and Exhibition Centre
Supported by CSL Behring

ASCIA 2019 Gala Dinner

Thursday 5 September, 19.00-23.00
Postal Hall, State Buildings
The Gala Dinner is an additional cost.

ASCIA 2019 Closing Function (including award presentations)


Friday 6 September, 17.00-18.00
Bellevue Ballroom Foyer
Perth Convention and Exhibition Centre

Special Requirements

It is important that you provide details of any special diet, special needs or disability assistance required when you register.



EXHIBITION FLOORPLAN




EXHIBITORS

Exhibitor	Stand No.	Category	Website/s
Abacus dx	2 - 3	Gold sponsor	www.abacusdx.com
Abbott	31 - 32	Diamond sponsor	www.abbottnutrition.com.au
Allergend	26	Exhibitor	www.allergend.com.au
Allergy & Anaphylaxis Australia	12	Exhibitor - patient support	www.allergyfacts.org.au
Allergy New Zealand	13	Exhibitor - patient support	www.allergy.org.nz
AMSL Allergy/NZMSL	35	Gold sponsor	www.amsl.com.au www.nzms.co.nz
ARRC	16	Exhibitor - patient support	www.autoimmune.org.au
AusEE	14	Exhibitor - patient support	www.ausee.org
AusPIPS	20	Exhibitor - patient support	www.auspips.org.au
Bayer	5 - 6	Gold sponsor	www.bayer.com.au
Care Pharma	8	Exhibitor	www.carepharmaceuticals.com.au
CSL Behring	27 - 30	Diamond sponsor	www.cslbehring.com.au
DBV Technologies	1	Platinum sponsor	www.dbv-technologies.com
Ego Pharmaceuticals	50	Exhibitor	www.egopharm.com
ENT Technologies	23	Exhibitor	www.enttech.com.au
Ferrer Pharma	52	Exhibitor	www.ferrerpharma.com.au
Gamma Allergy	55	Exhibitor	www.gammaallergy.com.au
Grifols	21 - 22	Gold sponsor	www.grifols.com
GSK	24 - 25	Gold sponsor	www.gsk.com.au
HAE Australasia	17	Exhibitor - patient support	www.haeaustralasia.org.au
IDFA	18	Exhibitor - patient support	www.idfa.org.au
IDFNZ	19	Exhibitor - patient support	www.idfnz.org.nz
LTR Medical	37	Exhibitor	www.ltrmedical.com
MedicAlert Foundation	9	Exhibitor	www.medicalert.org.au
Mylan	41 - 44	Diamond sponsor	www.mylan.com.au
National Allergy Strategy	11	Exhibitor - patient support	www.nationalallergystrategy.org.au
National Blood Authority	39	Exhibitor	www.blood.gov.au
NeilMed Pharmaceuticals	54	Exhibitor	www.neilmed.com
Nestle	7	Exhibitor	www.nestlehealthscience.com.au
Novartis	36, 38, 40	Platinum sponsor	www.novartis.com.au
Nutricia	33 - 34	Platinum sponsor	www.nutricia.com.au
RACP	10	Exhibitor	www.racp.edu.au
Sanofi	49, 51, 53	Platinum sponsor	www.sanofi.com.au
Seqirus	47 - 48	Gold sponsor	www.seqirus.com.au
Stallergenes Greer	45 - 46	Platinum sponsor	www.stallergenesgreer.com/australia-new-zealand
Takeda	4	Gold sponsor	www.takeda.com/en-au
TAMS	15	Exhibitor - patient support	www.mastocytosis.org.au



ASCIA2019

ASCIA 2019 Conference App HOW TO DOWNLOAD



New Users

- 1 Download**
Go to the App Store or Google Play and search for "myINTERACT"
- 2 Register**
Tap on "Create account" and enter email address and unique password
- 3 Connect**
Tap on the +, select "Enter Access Code" and type the code below

Existing Users

- 1 Update**
Ensure you have the latest version of myINTERACT
- 2 Connect**
Tap on the +, select "Enter Access Code" and type the code below



Thanks to our app sponsors



myINTERACT is also available at <https://my.interact.technology>. Login with the same account details. Need Help? Email support@interact.technology




Participating in Q&A sessions GUIDE FOR DELEGATES

How it works

- Ask or vote on a question you would like addressed in real time via myINTERACT using your mobile device
- The page is automatically reordered so most popular questions appears first. The number in the left hand column indicates the number of votes
- Includes option to direct questions to specific speakers



How do I submit a question?



- 1 Tap on Q&A**
- 2 Select the appropriate session**
- 3 Tap 'Ask' to submit a question or tap arrow to upvote a question**

PROGRAM SUMMARY

ASCIA 2019

Tuesday 3 Sept	Wednesday 4 Sept	Thursday 5 Sept	Friday 6 Sept
CFAR Symposium	ASCIA Conference Day 1	ASCIA Conference Day 2	ASCIA Conference Day 3
Registration	Registration	Registration	Registration
	Breakfast Session: National Allergy Strategy	Breakfast Session: JCTC Forum for Supervisors and Trainees	Breakfast Session: Primary Immunodeficiency (PID) Cases
Session 1: Presentations	Development of Allergy Plenary	Pathophysiology and Diagnostics Plenary	Immunodeficiency Plenary
Morning Tea	Morning Tea	Morning Tea	Morning Tea
Session 2: Presentations Hot Publications I	Non IgE Mediated Immune Conditions Symposium	Immunology of the Skin Symposium	Immunodeficiency Symposium
Lunch	Lunch	Lunch	Lunch
Session 3: Presentations Hot Publications II	Allergen Immunotherapy Symposium Panel Discussion: OIT for Food Allergy	ASCIA AGM Autoimmunity Symposium	ASCIA / ANZAAG Drug Allergy Symposium I
Afternoon Tea	Afternoon Tea	Afternoon Tea	Afternoon Tea
CFAR-ASCIA Session: Food Allergy in Adolescence and Transition Panel Discussion	Basten Oration Poster Rounds	Clinical Grand Rounds Panel Discussion: Drug Allergy	ASCIA / ANZAAG Drug Allergy Symposium II
	Welcome Function	Gala Dinner	Closing Function

Thursday 5 – Friday 6 Sept	Thursday 5 Sept	Friday 6 Sept	Saturday 7 Sept
ASCIA Medical Associate Sessions	ASCIA Dietitians Day	ASCIA Conference Nurses Day	ASCIA Immunopathology Day
Registration	Registration	Registration	Registration
Breakfast Session (Friday): ASCIA Medical Associates Meeting	Breakfast Session: ASCIA Dietitians Committee Meeting	Breakfast Sessions: ASCIA Nurses Committee Meeting ASCIA Nurses Special Interest Groups	
Session 3 (Friday): Community Food Challenges Symposium	Session 1: Management Update - Cow's Milk and Egg Allergy	Session 1: Oral Immunotherapy for Food	Session 1
Morning Tea	Morning Tea	Morning Tea	Morning Tea
Session 4 (Friday): Skin Prick Testing Workshop	Session 2: Primary Immunodeficiency and Nutrition	Session 2: Psychology and Allergy	Session 2
Lunch	Lunch	Lunch	Lunch
ASCIA AGM Session 1 (Thursday): Non-allergic Rhinitis and Polyposis Symposium	ASCIA AGM Session 3: Oral Immunotherapy for Food Allergy	Session 3: Primary Immunodeficiency	Session 3
Afternoon Tea	Afternoon Tea	Afternoon Tea	Afternoon Tea
Session 2 (Thursday): New Approaches to Allergic Rhinitis Symposium Paediatric Food Allergy Case Studies	Session 4: Beyond the Clinical Consultation	Session 4: Vaccination in Immunodeficiency	
Gala Dinner	Gala Dinner	Closing Function	

For information about events being held in conjunction with the ASCIA 2019 Conference in Perth, go to:
www.anzaag.com/Events.aspx

Eighth Australian and New Zealand Anaesthetic Allergy Group (ANZAAG) Symposium
Saturday 7 September 2019, 8.45am-12.30pm

<https://daa.asn.au/member-community/blog/centre-for-advanced-learning/food-allergy-and-intolerance/>
ASCIA-DAA CAL (Centre for Advanced Learning) Food Allergy and Intolerance Course for Dietitians
Friday 6 and Saturday 7 September 2019

TUESDAY 3 SEPTEMBER 2019

Meeting Rooms 1-3, Perth Convention and Exhibition Centre, Western Australia



08.00-09.00	Registration	
09.00-10.30	SESSION 1	
09.00-09.10	Welcome and introductions	CFAR Chief Investigators
09.10-09.50	Recent advances in food allergy research	Prof Philippe Eigenmann
09.50-10.00	The real cause for food recalls and allergic reactions in Australia	Dr Giovanni Zurzolo
10.00-10.30	Cost-effectiveness of food allergy management and treatment	A/Prof Matthew Greenhawt
10.30-11.00	Morning Tea	
11.00-12.30	SESSION 2	
11.00-11.15	Novel and emerging treatments for food allergy	Prof Dianne Campbell
11.15-11.30	Probiotic food OIT: long-lasting impact on immune responses and QoL	Prof Mimi Tang
11.30-11.45	Advances in epigenetics of food allergy	Dr David Martino
11.45-12.00	Advances in tree nut allergy diagnostics and prevention	Dr Kirsten Perrett
12.00-12.30	Hot publications in food allergy research I	
12.30-13.30	Lunch	
13.30-15.00	SESSION 3	
13.30-13.45	Update on the role of skin barrier in food allergy prevention	A/Prof Adrian Lowe
13.45-14.00	Update on dietary interventions for food allergy prevention	A/Prof Debbie Palmer
14.00-14.10	Breast feeding in the prevention of food allergy	Dr Merryn Netting
14.10-14.40	Hot publications in food allergy research II	
14.40-15.00	Food allergy in teenagers and young adults: the current Australian approach	Sandra Vale
15.00-15.30	Afternoon Tea	
15.30-17.10	CFAR-ASCI A JOINT SESSION: FOOD ALLERGY IN ADOLESCENCE AND TRANSITION	
15.30-16.15	Food allergies in adolescents and young adults: issues and solutions	A/Prof Matthew Greenhawt
16.15-17.00	Panel discussion: Food allergies in teenagers and young adults - how do we keep them safe? Moderator: Prof Jo Douglass Panel: A/Prof Matthew Greenhawt, Prof Connie Katelaris, Maria Said, Briony Tyquin, Sandra Vale, A/Prof Carina Venter.	
17.00-17.10	Conclusions and wrap-up	CFAR Chief Investigators

TUESDAY 3 SEPTEMBER 2019

Meeting Rooms 1-3, Perth Convention and Exhibition Centre, Western Australia



12.00-12.30	Hot Publications I
12.00-12.06	Dr Vicki McWilliam - Murdoch Children's Research Institute, Victoria SPT predictive values for the outcome of cashew challenges in children
12.06-12.18	Dr Elecia Johnston - James Cook University, Queensland Patients allergic to fish tolerate ray based on the low allergenicity of its parvalbumin Variability of allergens in commercial fish extracts for skin prick testing
12.18-12.30	Dr Sam Mehr - Royal Children's Hospital, Victoria Innate immune activation occurs in acute food protein-induced enterocolitis syndrome reactions Differentiating acute food protein-induced enterocolitis syndrome from its mimics: a comparison of clinical features and routine laboratory biomarkers
14.10-14.40	Hot Publications II
14.10-14.15	Victoria Soriano - Murdoch Children's Research Institute, Victoria Earlier ingestion of peanut following changes to infant feeding guidelines: the EarlyNuts study
14.15-14.20	Dr Rachel Peters - Murdoch Children's Research Institute, Victoria Food allergy at 1 year predicts persistence of eczema at 6 years
14.20-14.25	Dr Marie Estcourt - Telethon Kids Institute, Western Australia Case-control study of the association of whole cell pertussis vaccination and IgE-mediated food allergy
14.25-14.30	Prof Valerie Verhasselt - The University of Western Australia The presence of both ovalbumin and ovalbumin specific IgG in breastmilk is associated with a decreased risk of egg allergy in infants
14.30-14.35	Dr Patricia Macchiaverni - The University of Western Australia A role for early oral exposure to house dust mite proteases in food allergy susceptibility
14.35-14.40	A/Prof Adrian Lowe - The University of Melbourne, Victoria The role of early life food sensitization in adolescent lung function: results from 2 birth cohort studies

CONFERENCE DAY 1 PROGRAM

WEDNESDAY 4 SEPTEMBER 2019

Bellevue Ballroom 2, Perth Convention and Exhibition Centre, Western Australia

07.30-09.00	Registration	
07.30-08.45	BREAKFAST SESSION: National Allergy Strategy Chair: Dr Preeti Joshi National Allergy Strategy progress report 2015-2019 A/Prof Richard Loh, Maria Said, Sandra Vale. Breakfast will be available from 07.30-07.45 <i>This breakfast session is supported by the National Allergy Strategy</i>	
08.45-09.00	Welcome to the ASCIA 2019 Conference Chairs: Dr Brynn Wainstein, ASCIA President Prof Michaela Lucas, ASCIA President Elect and Conference Chair	
09.00-10.30	DEVELOPMENT OF ALLERGY PLENARY Chairs: Ingrid Roche, Dr Brynn Wainstein	
09.00-09.30	Does the interplay of diet diversity and diet indices with the microbiome, immune system and epigenetics prevent allergic diseases? A/Prof Carina Venter	
09.30-10.00	The immunology of atopic dermatitis Prof Mark Boguniewicz	
10.00-10.30	Allergy as a reflection of dysbiotic drift: the importance of ecological approaches to immune health Prof Susan Prescott	
10.30-11.00	Morning Tea – Bellevue Ballroom 1 (Exhibition Hall)	
11.00-12.30	NON IGE MEDIATED IMMUNE CONDITIONS SYMPOSIUM Chairs: Dr Colin Somerville, Dr Lara Ford	
11.00-11.30	Hereditary angioedema (HAE) management update Prof Timothy Craig	
11.30-12.00	Eosinophilic esophagitis (EoE) update Prof Evan Dellon	
12.00-12.30	Food protein-induced enterocolitis syndrome (FPIES) update Dr Sam Mehr	
12.30-13.30	Lunch – Bellevue Ballroom 1 (Exhibition Hall)	
13.30-15.00	ALLERGEN IMMUNOTHERAPY SYMPOSIUM Chairs: Dr Ray Mullins, Dr Celia Zubrinich	
13.30-14.00	Novel insights into allergic rhinitis Prof Peter Hellings	
14.00-14.30	Oral immunotherapy (OIT) for food allergy update Prof Hugh Sampson	
14.30-15.00	Panel discussion: Is OIT the treatment for all food allergies? Panel members: Prof Hugh Sampson, Prof Peter Hellings, A/Prof Carina Venter, A/Prof Matthew Greenhawt, Prof Mimi Tang.	
15.00-15.30	Afternoon Tea – Bellevue Ballroom 1 (Exhibition Hall)	
15.30-16.30	BASTEN ORATION ASCIA, A&AA, and the National Allergy Strategy Blood, Sweat and Tears: Celebrating Success Chair: Dr Richard Nolan A/Prof Richard Loh	
16.30-18.00	WELCOME FUNCTION AND POSTER ROUNDS - Bellevue Ballroom Foyer	

CONFERENCE DAY 2 PROGRAM

THURSDAY 5 SEPTEMBER 2019

Bellevue Ballroom 2, Perth Convention and Exhibition Centre, Western Australia

07.30-09.00	Registration	
07.30-08.45	BREAKFAST SESSION: JCTC forum for supervisors and trainees Chair: Dr Jan Sinclair Breakfast will be available from 07.30-07.45 <i>This breakfast session is supported by ASCIA</i>	
09.00-10.30	PATHOPHYSIOLOGY AND DIAGNOSTICS PLENARY Chairs: Dr Christine Bundell, Dr Michael O'Sullivan	
09.00-09.35	Mast cell disorders and testing for mast cells Prof Mariana Castells	
09.35-10.10	Ontogeny of allergy and novel diagnostics Prof Hugh Sampson	
10.10-10.30	Clinical research presentations (CRP1, CRP2) Refer to page 28 for details Prof Sinthia Bosnic-Anticevich, Dr Narinder Kaur	
10.30-11.00	Morning Tea – Bellevue Ballroom 1 (Exhibition Hall)	
11.00-12.30	IMMUNOLOGY OF THE SKIN SYMPOSIUM Chairs: Dr Tracy Markus, Dr Kathryn Patchett	
11.00-11.35	Atopic dermatitis: towards targeted therapy Prof Mark Boguniewicz	
11.35-12.10	Angioedema and urticaria, pathogenesis, clinical differentials and management Prof Timothy Craig	
12.10-12.30	Clinical research presentations (CRP3, CRP4) Refer to page 28 for details Prof Connie Katelaris AM, A/Prof Kristina Rueter	
12.30-13.30	Lunch – Bellevue Ballroom 1 (Exhibition Hall)	
13.30-14.00	ASCIA AGM Chair: Dr Brynn Wainstein	
14.00-15.00	AUTOIMMUNITY SYMPOSIUM Chairs: Dr Patricia Martinez, A/Prof Mina John	
14.00-14.30	Systemic lupus erythematosus (SLE) management update Dr Ming Wei Lin	
14.30-15.00	Vasculitis and mimics of vasculitis Prof Dominic Mallon	
15.00-15.30	Afternoon Tea – Bellevue Ballroom 1 (Exhibition Hall)	
15.30-17.00	CLINICAL GRAND ROUNDS (CGR) CGR cases 1-13 will be presented by advanced trainees Chairs: Dr Tiffany Hughes, A/Prof Kristina Rueter	
17.00-18.00	DRUG ALLERGY PANEL DISCUSSION Antibiotics and Allergy in our Community Chair: Dr Norman Swan Panel: Prof Michaela Lucas, Prof Mariana Castells, Dr Jason Trubiano, A/Prof Kristina Rueter, Dr Richard Choong, Maria Said. <i>This session is supported by The University of Western Australia</i>	
19.00-23.00	GALA DINNER – Postal Hall, State Buildings	

FRIDAY 6 SEPTEMBER 2019

Bellevue Ballroom 2, Perth Convention and Exhibition Centre, Western Australia

07.30-09.00	Registration	
07.30-08.45	BREAKFAST SESSION: Primary immunodeficiency (PID) clinical grand rounds (CGR) cases CGR cases 14-21 will be presented by advanced trainees Chairs: Dr Theresa Cole, Dr Vanessa Bryant Breakfast will be available from 07.30-07.45 <i>This breakfast session is supported by unrestricted grants from CSL Behring and JMF Centre for PID Melbourne</i>	
09.00-10.30	IMMUNODEFICIENCY PLENARY Chairs: Dr Andrew McLean-Tooke, Dr Joanne Smart	
09.00-09.30	Consensus on immunoglobulin therapy in non-classical and secondary immunodeficiency in the UK	Dr Tomaz Garcez
09.30-10.00	Update on primary immunodeficiency and genomic diagnosis	Dr Paul Gray
10.00-10.30	Antibody deficiencies	Dr Vanessa Bryant
10.30-11.00	Morning Tea - Bellevue Ballroom 1 (Exhibition Hall)	
11.00-12.30	IMMUNODEFICIENCY SYMPOSIUM Chairs: Dr Charlotte Slade, Dr Lloyd D'Orsogna	
11.00-11.40	Newborn screening in New Zealand and Australia	Dr Jan Sinclair, Dr Melanie Wong
11.40-12.10	Vaccinations and immunodeficiency	A/Prof Peter Richmond
12.10-12.30	Clinical research presentations (CRP5, CRP6) Refer to page 28 for details	A/Prof Ilia Voskoboinik, Dr Jin Yan Yap
12.30-13.30	Lunch - Bellevue Ballroom 1 (Exhibition Hall)	
13.30-15.00	ANZAAG / ASCIA DRUG ALLERGY SYMPOSIUM I Chairs: Prof Michaela Lucas, Dr Paul McAleer	
13.30-14.05	Managing patients with mast cell disorders	Prof Mariana Castells
14.05-14.40	Management of penicillin allergies	Prof Michaela Lucas
14.40-15.00	Management of cephalosporin allergies	Prof Connie Katelaris AM
15.00-15.30	Afternoon Tea - Bellevue Ballroom 1 (Exhibition Hall)	
15.30-17.00	ANZAAG / ASCIA DRUG ALLERGY SYMPOSIUM II Chairs: Dr James Yun, Dr Paul McAleer	
15.30-16.05	Unusual medication allergies	Dr Tomaz Garcez
16.05-16.40	Severe cutaneous adverse reactions in Australia - approaches to prevention, drug causality and safe prescribing	Dr Jason Trubiano
16.40-17.00	Allergy and autoimmunity in oncology	Dr Jack Bourke
17.00-18.00	CLOSING FUNCTION - Bellevue Ballroom Foyer	

Number	Name	Paper title	Organisation
ALLERGY/AUTOIMMUNITY			
CGR1	Dr Yeri Ahn	Check your -itis	Auckland District Health Board
CGR2	Dr Syed Ali	A meaty dress?	Royal Adelaide Hospital
CGR3	Dr Pei Dai	Crazy for sleep	Westmead Hospital
CGR4	Dr Lisa Horgan	A case of ulcerative colitis-related tracheobronchitis responding to infliximab	Perth Children's Hospital
CGR5	Dr Adrian Lee	Neonatal lupus erythematosus: a model for passively acquired autoimmunity	Flinders Medical Centre / SA Pathology
CGR6	Dr Wei-I Lee	Autoimmune primary dysautonomia	Royal Adelaide Hospital
CGR7	Dr Natasha Moseley	Aseptic abscesses syndrome: a paediatric case report with a literature review of management	Perth Children's Hospital
CGR8	Dr Lavinia Petrescu	Life-threatening atypical haemolytic uremic syndrome in an adult patient with SLE	The Canberra Hospital
CGR9	Dr Sam Salman	A case of mistaken identity: disseminated mycobacterium avium complex infection complicated by interferon-gamma autoantibodies concealed by diagnosis of metastatic breast cancer	Sir Charles Gairdner Hospital
CGR10	Dr Elina Tan	A nutty consequence of allogeneic stem cell transplant	Sir Charles Gairdner Hospital
IMMUNODEFICIENCY			
CGR11	Dr Chaitanya Bodapati	The case of an undefined combined immune deficiency	The Children's Hospital at Westmead
CGR12	Dr Josh Chatelier	Management of invasive aspergillosis in chronic granulomatous disease	Alfred Health
CGR13	Dr Jonathan Emerson	Recurrent infections and inflammatory bowel disease - is it just because of the immunosuppression?	Westmead Hospital
CGR14	Dr Alice Grey	A complex problem with a genetic answer?	Royal Prince Alfred Hospital
CGR15	Dr Hannah Hu	Serum factor conferring novel susceptibility to intracellular organisms, including non-tuberculous mycobacteria	Concord Repatriation General Hospital
CGR16	Dr Celina Jin	Acquired c1 esterase inhibitor deficiency caused by b cell lymphoproliferative disorder	The Canberra Hospital
CGR17	Dr Ashisha Kallukaran	Pneumocystis jiroveci pneumonitis in a neonate	Queensland Children's Hospital
CGR18	Dr Matthew Krummenacher	Activated pi3-kinase delta syndrome (APDS) and t-cell lymphoma	Royal Adelaide Hospital
CGR19	Dr Elize O'Reilly	An unexpected diagnosis	Queensland Children's Hospital
CGR20	Dr Shruti Swamy	The unwanted superpower	Sydney Children's Hospital Network
CGR21	Dr Timothy West	A 16-year-old boy with a novel germline mutation causing recurrent fungal infections	Liverpool Hospital

THURSDAY 5 SEPTEMBER 2019

Meeting Room 2, Perth Convention and Exhibition Centre, Western Australia

07.30-09.00	Registration	
07.15-08.15	BREAKFAST SESSION: ASCIA Dietitians committee meeting Chair: Kathy Beck Breakfast will be available from 07.15-07.30 <i>This breakfast session is supported by ASCIA</i>	
08.30-10.30	SESSION 1: MANAGEMENT UPDATE - COW'S MILK AND EGG ALLERGY Chair: Kathy Beck, Belinda Martin	
08.30-08.40	Welcome	Kathy Beck
08.40-09.20	Choosing suitable milk substitutes for cow's milk allergy	A/Prof Carina Venter
	Climbing the ladder to tolerance:	
09.20-09.40	Using egg ladders for IgE mediated egg allergy	Dr Merryn Netting
09.40-10.10	iMAP guidelines for non IgE mediated cow's milk allergy	A/Prof Carina Venter
10.10-10.30	Milk ladders and IgE mediated cow's milk allergy	Dr Vicki McWilliam
10.30-11.00	Morning Tea - Bellevue Ballroom 1 (Exhibition Hall)	
11.00-12.30	SESSION 2: PRIMARY IMMUNODEFICIENCY (PID) AND NUTRITION Chairs: Tanya Collins, Dr Anne Swain	
11.00-11.30	An overview of PID for dietitians	Dr Patrick Quinn
11.30-12.00	Malnutrition in PID	Amanda Jackson
12.00-12.30	Immunodeficiency case studies	Amanda Jackson, Kathy Beck
12.30-13.30	Lunch - Bellevue Ballroom 1 (Exhibition Hall)	
13.30-14.00	ASCIA ANNUAL GENERAL MEETING (AGM) Chair: Dr Brynn Wainstein All ASCIA members are invited to the AGM in Bellevue Ballroom 2	
14.00-15.00	SESSION 3: ORAL IMMUNOTHERAPY (OIT) FOR FOOD ALLERGY Chairs: Anna Richards, Evania Marlow	
14.00-14.45	The brave new world of OIT - implications for Australian clinicians	Dr Dean Tey
14.45-15.00	OIT for food allergy in adults	Dr Michael O'Sullivan
15.00-15.30	Afternoon Tea - Bellevue Ballroom 1 (Exhibition Hall)	
15.30-17.15	SESSION 4: BEYOND THE CLINICAL CONSULTATION Chairs: Ingrid Roche, Laura Ryan	
15.30-16.00	Making research a part of everyday clinical practice	A/Prof Carina Venter
16.00-16.20	Allergy practice and research in the online space	Dr Merryn Netting, A/Prof Carina Venter
16.20-16.45	National Allergy Strategy update	Sandra Vale
16.45-17.15	Q&A Panel: Burning questions, difficult cases discussion A/Prof Carina Venter, Dr Merryn Netting, Dr Vicki McWilliam, Kathy Beck, Anna Richards	
19.00-23.00	GALA DINNER - Postal Hall, State Buildings	

FRIDAY 6 SEPTEMBER 2019

Meeting Room 2, Perth Convention and Exhibition Centre, Western Australia

07.30-09.00	Registration	
07.30-08.45	BREAKFAST SESSIONS: Annual ASCIA nurses committee meeting ASCIA Nurses special interest groups Chair: Sacha Palmer Breakfast will be available from 07.30-07.45 This breakfast session is supported by ASCIA	
09.00-10.30	ORAL IMMUNOTHERAPY (OIT) FOR FOOD ALLERGY Chairs: Val Noble, Rebecca Sertori	
09.00-09.30	OIT and implications for Australia	A/Prof Richard Loh
09.30-10.00	An overview of OIT	Prof Mimi Tang
10.00-10.30	Panel discussion: A/Prof Richard Loh, Prof Mimi Tang, Maria Said, Carolina Valerio	
10.30-11.00	Morning Tea - Bellevue Ballroom 1 (Exhibition Hall)	
11.00-12.30	PSYCHOLOGY AND ALLERGY Chairs: Sacha Palmer, Terri Williams	
11.00-11.30	The use of psychologists in allergies	Robyn Willis
11.30-11.45	Parent presentation	Kara Craig
11.45-12.00	Teen / young adult presentation	Lachlan Schultz
12.00-12.30	Panel discussion: Robyn Willis, Kara Craig, Lachlan Schultz, Maria Said	
12.30-13.30	Lunch - Bellevue Ballroom 1 (Exhibition Hall)	
13.30-15.00	PRIMARY IMMUNODEFICIENCY Chairs: Terri Williams, Lotta Ekstrom	
13.30-14.15	Immunodeficiency, genetic testing and counselling	Dr Michael O'Sullivan, Sarah O'Sullivan
14.15-15.00	Severe combined immunodeficiency (SCID) and haematopoietic stem cell transplants (HSCT)	Dr Theresa Cole
15.00-15.30	Afternoon Tea - Bellevue Ballroom 1 (Exhibition Hall)	
15.30-16.00	Vaccination in immunodeficiency Chairs: Esther Edward, Vicki O'Brien	Dr Andrew McLean-Tooke
17.00-18.00	CLOSING FUNCTION - Bellevue Ballroom Foyer	

MEDICAL ASSOCIATE SESSIONS

IMMUNOPATHOLOGY DAY

THURSDAY 5 SEPTEMBER 2019 14.00-17.00

Meeting Room 1, Perth Convention and Exhibition Centre, Western Australia

12.30-13.30	Lunch – Bellevue Ballroom 1 (Exhibition Hall)	
13.30-14.00	ASCIA AGM Chair: Dr Brynn Wainstein All ASCIA members are invited to the AGM in Bellevue Ballroom 2	
14.00-15.00	SESSION 1: NON-ALLERGIC RHINITIS AND POLYPOSIS Chair: Dr Victoria Smith	Dr Raewyn Campbell, Dr Marius Botha
15.00-15.30	Afternoon Tea – Bellevue Ballroom 1 (Exhibition Hall)	
15.30-16.30	SESSION 2: NEW APPROACHES TO ALLERGIC RHINITIS Chair: Dr Victoria Smith	Dr Ray Mullins, Dr Nick Cooling, Dr Jessica Tattersall
16.30-17.00	SESSION 3: PAEDIATRIC FOOD ALLERGY CASE STUDIES	Dr Joanne Smart
19.00-23.00	GALA DINNER – Postal Hall, State Buildings	

FRIDAY 6 SEPTEMBER 2019 08.00-12.30

Meeting Room 1, Perth Convention and Exhibition Centre, Western Australia

08.00-09.00	BREAKFAST SESSION: ASCIA Medical Associates meeting Chair: Dr Victoria Smith	
09.00-10.30	SESSION 4: COMMUNITY FOOD CHALLENGES Chair: Dr Victoria Smith	
09.00-09.30	Evidence based guide	Dr Nick Cooling
09.30-10.30	Practical applications	Dr Kathryn Heyworth, Dr Benedicta Itotoh
10.30-11.00	Morning Tea – Bellevue Ballroom 1 (Exhibition Hall)	
11.00-12.30	SESSION 5: SKIN PRICK TESTING WORKSHOP	Dr Anna Gilmour
12.30-13.30	Lunch – Bellevue Ballroom 1 (Exhibition Hall)	

SATURDAY 7 SEPTEMBER 2019

Avon and Helena Rooms, Adina Apartment Hotel, Mounts Bay Rd, Perth, Western Australia

08.00-08.30	Registration	
08.30-10.30	SESSION 1 Chair: Dr Ben McGettigan	
08.30-09.15	Periodic fever syndrome (PFS) genotyping	Dr Lloyd D'Orsogna
09.15-10.00	Newborn screening assay (KRECS/TRECS): lessons learnt	Dr Shannon Brothers, Dr Melanie Wong
10.00-10.30	Interstitial lung disease	Prof Fiona Lake
10.30-11.00	Morning Tea	
11.00-13.00	SESSION 2 Chair: Dr Chris Bundell	
11.00-11.45	Myositis update	Dr Merrilee Needham
11.45-12.15	Neuroimmunology: the MAYO experience	Dr Kevin O'Connor
12.15-12.45	Novel and rare anti-neuronal antibodies: cases and discussion of current literature	Dr Ben McGettigan
12.45-13.00	Selected abstracts	
13.00-14.00	Lunch	
14.00-15.30	SESSION 3 Chair: Dr Luckshman Ganeshanandan	
14.00-14.30	Laboratory testing for anti TNF drugs	Melissa Sam
14.30-15.00	Anti-drug antibody screening and how is the information used	Dr Lena Thin
15.00-15.30	Quality assurance program (QAP) 2019	Dr Frederick Lee
15.30	MEETING CLOSED	

Professor Mark Boguniewicz MD

Professor, Division of Allergy-Immunology

Department of Pediatrics

National Jewish Health and University of Colorado School of Medicine, USA

Professor Mark Boguniewicz, is a professor in the Division of Allergy-Immunology, Department of Pediatrics, at National Jewish Health and University of Colorado School of Medicine. He completed his residency in pediatrics at Children's Hospital of Michigan and fellowship in allergy-immunology and rheumatology at Children's Hospital and Harvard Medical School in Boston. He is board certified in pediatrics and allergy-immunology.

Professor Boguniewicz is a Fellow of the American Academy of Allergy, Asthma, and Immunology (AAAAI), past Chair of the Dermatologic and Ocular Diseases Interest Section and past Chair of the Eczema Committee. He is also a Fellow of the American College of Allergy, Asthma, and Immunology (ACAAI). He is on the editorial board of Journal of Allergy and Clinical Immunology: In Practice. He served on the Joint Taskforce on Topical Calcineurin Inhibitors of the AAAAI and ACAAI and was co-chair of the treatment section of the European Academy of Allergology and Clinical Immunology/AAAAI/PRACTALL Consensus Group for atopic dermatitis. He has served on the Joint Task Force of the AAAAI/ACAAI for the 2004 and 2012 Practice Parameter for Atopic Dermatitis. He co-chaired the Expert Panel on Management of Moderate-to-Severe Atopic Dermatitis and chaired the Atopic Dermatitis Yardstick project.

Professor Boguniewicz's research focuses on immunopathogenesis and new treatments for atopic dermatitis. He is an investigator of the NIH Atopic Dermatitis Research Network. He has lectured at many national and international meetings and has over 350 peer-reviewed articles, reviews, chapters and abstracts published. He is the recipient of several Pediatric Allergy-Immunology Fellows Outstanding Teacher Award, the 2002 Faculty Clinician of the Year Award, the 2006 AAAAI's Richard S. Farr Memorial Lectureship, and has been selected for Best Doctors in America. He is also the recipient of the 2013 AAAAI Distinguished Clinician Award.

Professor Mariana Castells MD PhD

Brigham and Women's Hospital

Boston Massachusetts USA

Professor Castells is a clinician, researcher and teacher at Brigham and Women's Hospital and Dana Farber Cancer Institute, USA. She is the Director of the Drug Hypersensitivity and Drug Desensitization Center, as well as the Director of the Mastocytosis Center, and has served as the Allergy and Immunology Training Program Director for 20 years.

Professor Castells served on the Board of Directors of The American Academy of Allergy, Asthma & Immunology (AAAAI), and is now the research chair director of the AAAAI Foundation. She is on the Board of Directors for the ABAI, and the Board of Directors for the Journal of Allergy and Clinical Immunology (JACI) and the JACI In Practice. She is on the council of the International College of Allergy (CIA) and has directed the International Drug Desensitization Meeting (DDIM) in Barcelona, Spain, yearly.

Professor Castells has spearheaded the evaluation and understanding of drug anaphylaxis and hypersensitivity, and provided desensitization protocols which are used as standards around the world, treating thousands of patients with cancer and chronic inflammatory diseases, maintaining these patients on their first line therapy.

Her research has uncovered mast cell inhibitory mechanisms which are pertinent to desensitization. She has been involved in the new diagnostic criteria for mast cell activation disorders and mastocytosis and heads clinical trials created at the Mastocytosis Center.

Professor Timothy Craig MD DO

Penn State University

Allergy Asthma and Immunology

Hershey, Pennsylvania USA

Professor Timothy Craig is a professor of medicine and pediatrics at Penn State University. He trained in the US Navy after which he started his academic career at the University of Iowa and then transferred to Penn State to start an Allergy and Immunology Program. He is the director of the Alpha-1-Deficiency Center at Penn State University.

Professor Craig is a distinguished educator, program director, section chief and a Fellow of the AAAAI, ACP, ACAAI and ACOI. He is the recipient of multiple teaching awards, has published over 250 manuscripts and has delivered over 350 invited lectures.

Professor Craig is proud to be a Vietnam Education Foundation Scholar.

Professor Craig's travel is supported by CSL Behring.

Professor Evan Dellon MD

Gastroenterologist

University of North Carolina, USA

Evan Dellon is a Professor of Medicine at the University of North Carolina School of Medicine. He joined the University of North Carolina (UNC) faculty and the Center for Esophageal Diseases and Swallowing (CEDAS) in 2008, where his main clinical focus is on disorders of swallowing, in particular eosinophilic esophagitis (EoE). He became Director of CEDAS in 2014, and is an Associate Editor for Clinical Gastroenterology and Hepatology.

Professor Dellon's main research interest is in the epidemiology, pathogenesis, diagnosis, treatment, and outcomes of eosinophilic esophagitis (EoE), and the eosinophilic GI diseases (EGIDs). He is widely published in this area, and collaborates with investigators all over the world. Dr. Dellon has received research funding from the National Institutes of Health, the American College of Gastroenterology, the American Gastroenterologic Association, the CURED Foundation (campaign urging research for eosinophilic disease), UNC, and a number of industry partners to study EoE and other EGIDs.

The goal of Professor Dellon's research is to improve the lives of patients with EoE and EGIDs by learning how to better diagnose, treat, and monitor the condition. He is widely published in this area, and collaborates with investigators all over the world.

Professor Dellon's travel is supported by Abbott.

Professor Philippe Eigenmann MD

Department of Paediatrics

Division of Paediatric Specialisations

Pathogenesis and Treatment of Food Allergies, University of Geneva

Professor Philippe Eigenmann is a pediatrician and allergist trained in Switzerland, and in the USA (Johns Hopkins Hospital, Baltimore). He is currently head of Pediatric Allergy at the University Hospitals of Geneva Switzerland. His main focus of research is food allergy with several ongoing studies focusing on early-life events of allergy, as well as on food allergy diagnosis.

Professor Eigenmann has published over 200 articles in international scientific journals. Since January 2018, he is editor-in-Chief of Pediatric Allergy and Immunology, the world leading journal in the field, and in the Editorial Board of Allergy. In addition to his scientific activity, he has been the chair of the European Academy of Allergology and Clinical Immunology (EAACI) section on Pediatrics, and president of the Swiss Society for Allergy and Immunology. He is also secretary of the EAACI-Clemens von Pirquet Foundation, a European foundation promoting research and education in pediatric allergy and immunology.

Dr Tomaz Garcez MBChB FRCP FRCPath

Consultant Immunologist at Manchester University NHS

Foundation Trust (MFT), Manchester, United Kingdom

Dr Garcez graduated from Aberdeen University in 1997 and completed postgraduate general professional training in Cardiff (adult medicine) and higher specialist training in Bristol (immunology and general internal medicine).

Dr Garcez was appointed to Central Manchester University Hospitals NHS Foundation Trust (CMFT) as consultant immunologist in July 2011. He leads the clinical and laboratory immunology service in MFT, he is the elected Chair of the UK Primary Immunodeficiency Network (UKPIN) and holds a seat on the immunology and allergy Clinical Reference Group (CRG - NHS England).

Dr Garcez is a member of the medical advisory panel for PID UK and represented the Fatal Anaphylaxis Register on the Royal College of Anaesthetists National Audit Project 6 Steering Panel.

Dr Garcez represents the UK on the European Network for Drug Allergy Task Force on Perioperative Hypersensitivity and on an international collaboration exploring Perioperative Hypersensitivity.

Dr Garcez's travel is supported by ANZAAG.

Associate Professor Matthew Greenhawt MD MBA MSc
Children's Hospital Colorado,
University of Colorado School of Medicine
Aurora, Colorado, USA

Associate Professor Matthew Greenhawt earned his medical degree from Tufts University School of Medicine, Boston, Massachusetts. Subsequently, he completed a pediatrics residency at Morgan Stanley Children's Hospital of New York-Presbyterian, Columbia Presbyterian Medical Center, New York, New York, and an allergy and clinical immunology fellowship at the University of Michigan in Ann Arbor, Michigan. He also holds an MBA from Tufts University and a master's of science degree in health and healthcare policy from the University of Michigan, Rackham School of Graduate Studies.

He is an Associate Professor with the Department of Pediatrics, Section of Allergy and Immunology at Children's Hospital Colorado and the University of Colorado School of Medicine. He serves as the director for the Children's Hospital Colorado Food Challenge and Research Unit.

Associate Professor Matthew Greenhawt is certified by the American Board of Pediatrics and American Board of Allergy and Immunology. He is a member of the American Academy of Allergy, Asthma & Immunology, American Academy of Pediatrics, American College of Allergy, Asthma & Immunology, and European Academy of Allergy and Clinical Immunology. He is an associate editor for the Annals of Allergy, Asthma and Immunology, and a member of the Joint Taskforce of Allergy Practice Parameters.

His research interests include establishment of phenotypes in food-allergic diseases, shared decision making, food allergy cost-effectiveness and comparative effectiveness research, food-allergic diseases health services and outcomes research, primary/secondary prevention and treatment of food allergy, and food allergy public policy. He has authored a number of peer-reviewed articles, abstracts, and book chapters. He serves as the current chair of the ACAAI Food Allergy Committee, and is a member of multiple AAAAI, ACAAI, and EAACI committees.

Associate Professor Greenhawt's travel is supported by CFAR and ASCIA.

Professor Peter Hellings MD
Professor of Rhinology, The University of Amsterdam's
Faculty of Medicine

In addition to his clinical work Professor Hellings is a researcher at the Clinical Immunology Laboratory. He is a member of the Flemish Agency for Care and Health, and has served as the Belgian representative in the European Academy of Facial Plastic Surgery. He is also the coordinator of the Excellence in Rhinoplasty course at KU Leuven since 2008.

Professor Peter Hellings conducts research into the mechanisms of chronic upper respiratory tract conditions, with a particular focus on allergic rhinitis and the non-allergic form that causes similar symptoms of stuffy nose and sneezing. A further area of interest is chronic rhinosinusitis, an inflammation of the mucous membrane in the nasal passage and sinuses, and in functional and aesthetic nasal problems.

Professor Hellings research spans the entire spectrum from animal research to in vitro and clinical studies. He has received various research grants and international awards for his scientific work. Hellings has also authored many articles in leading scientific journals including Nature, Lancet, Allergy, Journal of Allergy and Clinical Immunology, Journal of Clinical Investigation and Journal of Immunology.

Professor Hellings's travel is supported by Mylan.

Professor Hugh A Sampson MD
Icahn School of Medicine at Mount Sinai
New York, USA

Professor Sampson is the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine in New York and has nearly 35 years experience in translational research focusing on food allergic disorders and basic immunologic mechanisms responsible for these disorders.

Professor Sampson's research has been funded continuously by grants from the National Institutes of Health (NIH), including the Principal Investigator for the Consortium for Food Allergy Research.

Professor Sampson has published over 500 articles, 88 book chapters and co-edited seven books, primarily on clinical and immunopathogenic aspects of food allergic disorders. He was elected to membership in the National Academy of Medicine of the National Academies in 2003 for his research accomplishments.

Professor Sampson is the past-president of the American Academy of Allergy, Asthma and Immunology (AAAAI), and served on the Board of the World Allergy Organization (WAO). He has trained over 40 post-doctoral allergy/

immunology fellows, many of whom are now leaders in the field of food allergy. Professor Sampson has also served on the Editorial Board of five allergy journals, and is an Associate Editor of Pediatric Allergy & Immunology.

In November 2015, Professor Sampson stepped-down as Dean for Translational Biomedical Sciences at Mount Sinai to devote 40% of his time to DBV Technologies as their Chief Scientific Officer.

Professor Sampson's travel is supported by DBV Technologies.

Assistant Professor Carina Venter PhD
University of Colorado Children's Hospital, Colorado USA

Dr Venter is Assistant Professor of Pediatrics, Section of Allergy and Immunology at the Children's Hospital Colorado and University of Colorado Denver School of Medicine, where she is conducting research and working with children and adults with a range of food allergies.

Assistant Professor Venter is a past chair of the International Network of Dietitians and Nutritionists in Allergy (INDANA), and a member of the American Academy of Allergy and Clinical Immunology (AAAAI), American College of Allergy and Clinical Immunology (ACAAI), European Academy of Allergy and Clinical Immunology (EAACI) and the British Society of Allergy and Clinical Immunology (BSACI). She was also a member of the NICE (UK) food allergy guidelines.

Assistant Professor Venter has had numerous publications in international journals, and has authored book chapters and edited a book on Food Hypersensitivity.

Assistant Professor Venter moved from the UK in 2015 where she had been performing research into food allergies and allergy prevention as a Senior Lecturer at the University of Portsmouth and at the David Hide Centre on the Isle of Wight.

One of the highlights of Assistant Professor Venter's career has been her appointment to the Expert Panel of the National Institutes for Allergy and Infectious Diseases Peanut Allergy Prevention Guidelines, making her the only dietitian that has had presentation on official US and European food allergy guidelines.

Assistant Professor Venter's travel is supported by Abbott.

BASTEN ORATOR

Clinical Associate Professor Richard Loh
MBBS FRACP FAAAAI FAAAAI
Clinical Immunology and Allergy Specialist, Perth,
Western Australia

A/Prof Loh has more than 30 years of experience as a clinical immunology and allergy specialist.

He completed his medical degree from the University of Queensland in 1981 and has been a Fellow of the Royal Australasian College of Physicians (RACP) since 1988. From 1989 to 1993 A/Prof Loh was a Fellow in Immunology, Allergy and Rheumatology at the Children's Hospital in Boston, and Medical Officer at the Harvard Medical School. He is a Fellow of the American Academy of Allergy, Asthma and Immunology (AAAAI) and American College of Allergy, Asthma and Immunology (ACAAI).

For 25 years A/Prof Loh made a significant difference to allergy and clinical immunology in Australasia, as head of the Immunology department at Princess Margaret Hospital for Children. He transitioned this into a leading clinical immunology and allergy centre at the Perth Children's Hospital. A/Prof Loh encouraged allergy and immunology research in the hospital and has been involved in numerous studies.

A/Prof Loh joined ASCIA in 1994 and was President of ASCIA from 2012 to 2014. He was Chair of the ASCIA Anaphylaxis committee (2009-2012), co-Chair of the National Allergy Strategy (2016-2019) and co-founder of AIFA, the Allergy and Immunology Foundation of Australasia, formed in 2013. He has been an organising committee member for ASCIA Annual Scientific Meetings (2001, 2007) and Annual Conferences (2013, 2019) held in Perth, Western Australia. As Chair of the ASCIA Anaphylaxis committee, A/Prof Loh initiated the development of the world leading ASCIA anaphylaxis training courses, that were first launched in March 2010.

During his ASCIA Presidency, A/Prof Loh contributed through advocacy and vision, to the development of the first National Allergy Strategy for Australia, which he has co-chaired since it was initiated. This has enabled ASCIA and Allergy & Anaphylaxis Australia (AGAA), to gain government funding for important initiatives, that would not be feasible without this support.

SPEAKERS AND CHAIRS INDEX

ASCIA 2019

ASCIA 2019 CFAR SYMPOSIUM 3 September

PREFIX	FIRST NAME	LAST NAME	REGION	CFAR SYMPOSIUM SPEAKER	CFAR SYMPOSIUM CHAIR	CFAR SYMPOSIUM PANEL
Prof	Dianne	Campbell	NSW			
Prof	Jo	Douglass	VIC			
Prof	Philippe	Eigenmann	EU			
A/Prof	Matthew	Greenhawt	USA			
Prof	Connie	Katellaris	NSW			
A/Prof	Adrian	Lowe	VIC			
Dr	David	Martino	VIC			
Dr	Merryn	Netting	SA			
A/Prof	Debbie	Palmer	WA			
Dr	Kirsten	Perrett	VIC			
Ms	Maria	Said	NSW			
Prof	Mimi	Tang	VIC			
Ms	Briony	Tyquin	NSW			
Ms	Sandra	Vale	WA			
A/Prof	Carina	Venter	USA			
Dr	Giovanni	Zurzolo	VIC			

ASCIA 2019 CONFERENCE 4-6 September

PREFIX	FIRST NAME	LAST NAME	REGION	ASCIA CONFERENCE SPEAKER	ASCIA CONFERENCE CHAIR	ASCIA CONFERENCE PANEL
Prof	Mark	Boguniewicz	USA			
Dr	Jack	Bourke	WA			
Dr	Vanessa	Bryant	VIC			
Dr	Christine	Bundell	WA			
Prof	Mariana	Castells	USA			
Dr	Theresa	Cole	VIC			
Prof	Timothy	Craig	USA			
Prof	Evan	Dellon	USA			
Dr	Lloyd	D'Orsogna	WA			
Dr	Lara	Ford	NSW			
Dr	Tomaz	Garcez	UK			
Dr	Paul	Gray	NSW			
Prof	Peter	Hellings	EU			
Dr	Tiffany	Hughes	SA			
A/Prof	Mina	John	WA			
Dr	Preeti	Joshi	NSW			
Prof	Connie	Katellaris AM	NSW			
Dr	Ming-Wei	Lin	NSW			
A/Prof	Richard	Loh	WA			

Prof	Michaela	Lucas	WA			
Prof	Dominic	Mallon	WA			
Dr	Tracy	Markus	WA			
Dr	Patricia	Martinez	WA			
Dr	Paul	McAlear	SA			
Dr	Andrew	McLean-Tookey	WA			
Dr	Sam	Mehr	VIC			
Dr	Ray	Mullins	ACT			
Dr	Richard	Nolan	WA			
Dr	Michael	O'Sullivan	WA			
Dr	Kathryn	Patchett	NSW			
Prof	Susan	Prescott	WA			
A/Prof	Peter	Richmond	WA			
Ms	Ingrid	Roche	WA			
A/Prof	Kristina	Rueter	WA			
Ms	Maria	Said	NSW			
Prof	Hugh	Sampson	USA			
Dr	Jan	Sinclair	NZ			
Dr	Charlotte	Slade	VIC			
Dr	Joanne	Smart	VIC			
Dr	Colin	Somerville	WA			
Dr	Norman	Swan	NSW			
Prof	Mimi	Tang	VIC			
Dr	Jason	Trubiano	VIC			
Ms	Sandra	Vale	WA			
A/Prof	Carina	Venter	USA			
Dr	Brynn	Wainstein	NSW			
Dr	Melanie	Wong	NSW			
Dr	James	Yun	NSW			
Dr	Celia	Zubrinich	VIC			

ASCIA 2019 ASSOCIATE MEDICAL SESSIONS 5, 6 September

PREFIX	FIRST NAME	LAST NAME	REGION	MEDICAL ASSOCIATES DAY SPEAKER	MEDICAL ASSOCIATES DAY CHAIR
Dr	Marius	Botha	QLD		
Dr	Raewyn	Campbell	NSW		
Dr	Nick	Cooling	TAS		
Dr	Anna	Gilmour	NZ		
Dr	Kathryn	Heyworth	NSW		
Dr	Benedicta	Itotoh	WA		
Dr	Raymond	Mullins	ACT		
Dr	Joanne	Smart	VIC		
Dr	Victoria	Smith	TAS		
Dr	Jessica	Tattersall	NSW		

SPEAKERS AND CHAIRS INDEX

ASCIA 2019 DIETITIANS DAY 5 September

PREFIX	FIRST NAME	LAST NAME	REGION	DIETITIANS DAY SPEAKER	DIETITIANS DAY CHAIR	DIETITIANS DAY PANEL
Ms	Kathy	Beck	QLD			
Ms	Tanya	Collins	WA			
Ms	Amanda	Jackson	VIC			
Ms	Evania	Marlow	WA			
Ms	Belinda	Martin	WA			
Dr	Vicki	McWilliam	VIC			
Dr	Merryn	Netting	SA			
Dr	Michael	O'Sullivan	WA			
Dr	Patrick	Quinn	SA			
Ms	Anna	Richards	NZ			
Ms	Ingrid	Roche	WA			
Ms	Laura	Ryan	SA			
Dr	Anne	Swain	NSW			
Dr	Dean	Tey	VIC			
Ms	Sandra	Vale	WA			
A/Prof	Carina	Venter	USA			

ASCIA 2019 NURSES DAY 6 September


PREFIX	FIRST NAME	LAST NAME	REGION	NURSES DAY SPEAKER	NURSES DAY CHAIR	NURSES DAY PANEL
Dr	Theresa	Cole	VIC			
Ms	Kara	Craig	WA			
Ms	Esther	Edward	WA			
Ms	Lotta	Ekstrom	WA			
A/Prof	Richard	Loh	WA			
Dr	Andrew	McLean-Tooke	WA			
Ms	Val	Noble	WA			
Ms	Vicki	O'Brien	WA			
Dr	Michael	O'Sullivan	WA			
Ms	Sarah	O'Sullivan	WA			
Ms	Sacha	Palmer	SA			
Ms	Maria	Said	NSW			
Mr	Lachlan	Schultz	WA			
Ms	Rebecca	Sertori	NSW			
Prof	Mimi	Tang	VIC			
Ms	Carolina	Valerio	NSW			
Ms	Terri	Williams	WA			
Ms	Robyn	Willis	WA			

ASCIA 2019 IMMUNOPATHOLOGY DAY 7 September

PREFIX	FIRST NAME	LAST NAME	REGION	IMMUNOPATHOLOGY DAY SPEAKER	IMMUNOPATHOLOGY DAY CHAIR
Dr	Shannon	Brothers	NZ		
Dr	Christine	Bundell	WA		
Dr	Lloyd	D'Orsogna	WA		
Dr	Luckshman	Ganeshanandan	WA		
Prof	Fiona	Lake	WA		
Dr	Frederick	Lee	NSW		
Dr	Ben	McGettigan	WA		
Dr	Merrilee	Needham	WA		
Dr	Kevin	O'Connor	WA		
Ms	Melissa	Sam	NSW		
Dr	Lena	Thin	WA		
Dr	Melanie	Wong	NSW		

CLINICAL RESEARCH PRESENTATIONS

ID	PREFIX	FIRST NAME	LAST NAME	TITLE
CRP1	Prof	Sinthia	Bosnic-Anticevich	Paediatric allergic rhinitis: healthcare utilisation and hidden costs
CRP2	Dr	Narinder	Kaur	Does component testing improve prediction of peanut food challenge outcome in Australian children: a cross sectional study of peanut components and food challenge outcome
CRP3	Prof	Connie (Constance)	Katellaris AM	Dupilumab reduces severe asthma exacerbation rates and improves lung function across a range of prior exacerbations in patients with elevated type 2 biomarkers: the liberty asthma quest study
CRP4	A/Prof	Kristina	Rueter	Does early oral vitamin d supplementation and uv-light exposure have an impact on allergic disease outcome in infancy?
CRP5	A/Prof	Ilia	Voskoboinik	The many faces of familial haemophagocytic lymphohistiocytosis
CRP6	Dr	Jin Yan	Yap	Everolimus-induced remission of Kaposi's sarcoma secondary to cryptic ctla4 splicing and haploinsufficiency




CSL Behring is driven by our promise to save lives

Over a century ago in Melbourne, Australia, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions.

Today, as a leading global biotechnology company, that same promise has never been stronger. We are driven by our deep passion to serve thousands of patients and other stakeholders around the world.

Allergic Rhinitis



Are you certain your patients are receiving fast, effective and sustained relief?

Dymista[®] 125/50

azelastine hydrochloride/fluticasone propionate



Speed

Clinically relevant action within **30 minutes**¹⁻³



Strength

Twice the allergic rhinitis symptom relief vs. FP or AZE monotherapy^{4,5}



Sustainability

Sustained nasal symptom relief through 52 weeks of treatment^{4,6}

¹Placebo subtracted rT7SS compared to FP (P = 0.0013) and AZE (P = 0.0004) at day 14, post-hoc analysis (n = 610).
²Change from baseline in rTNSS score over 52 weeks (n = 388, Dymista vs. FP was P = 0.0048 at 28 weeks and P = 0.0642 at 52 weeks NS).

PBS Information: This product is not listed on the PBS.

Please review Product Information before prescribing.
 Full Product Information available on request by calling 1800 314 527.

Dymista[®] 125/50 (azelastine hydrochloride 125µg /fluticasone propionate 50 µg) nasal spray 17mL, 120 sprays). **Indications:** Symptomatic treatment of moderate to severe allergic rhinitis and rhino-conjunctivitis in adults and children 12 years and older where use of a combination (intranasal antihistamine and glucocorticoid) is appropriate. **Dosage:** Adults and adolescents (≥ 12 yrs): One spray in each nostril twice daily. **Contraindications:** Hypersensitivity to the active substance(s) or excipients. **Precautions:** Pregnancy (Cat B3) and lactation; operating machinery or driving motor vehicle; use with alcohol or other CNS depressants, somnolence; patients with recent nasal ulcers, surgery or injury to nose or mouth; patients susceptible to candida infections (e.g. diabetics); visual disturbance, glaucoma and/or cataracts; HPA axis effect/suppression, adrenal function impairment; tuberculosis or untreated respiratory infection; children and adolescents (< 12yrs); severe hepatic and renal impairment. **Interactions:** Cytochrome P450 3A4 inhibitors (potential increase fluticasone propionate exposure) eg: ritonavir, ketoconazole, cimetidine; CNS depressants. **Adverse Effects:** Common: headache, dysgeusia, unpleasant smell; Uncommon: epistaxis, nasal discomfort, sneezing, nasal dryness, cough, dry throat and irritation; Very rare: somnolence; nasal septal perforation; hypersensitivity including anaphylactic reactions, angioedema and bronchospasm. **Min PI Updated:** 19 Jun 2018.

MYLAN[®] is a registered trade mark of Mylan Inc. DYMISTA[®] is a registered trade mark of Meda AB. Copyright[®] 2019 Mylan N.V. All rights reserved. Mylan Health Pty Ltd. Level 1, 30-34 Hickson Rd, Millers Point, NSW, 2000, Australia. ABN: 29 601 608 771. Call: 1800 314 527. BB MYL3627b. DYM-2019-0451. Date of preparation: June 2019.

References: 1. Carr W, *et al.* J Allergy Clin Immunol. 2012;129(5):1282-9. 2. Dymista[®] 125/50 Approved Product Information. 3. Bousquet J, *et al.* J Allergy Clin Immunol Pract. 2018;6(5):1726-32. 4. Meltzer E, *et al.* Int Arch Allergy Immunol. 2013;161:369-77. 5. Hampel FC, *et al.* Ann Allergy Asthma Immunol. 2010;105:168-73. 6. Price D, *et al.* J Invest Allergol Clin Immunol. 2013;23(7):495-503.

Abbreviations: AZE, azelastine; FP, fluticasone propionate; NS, not significant; rT7SS, reflective total of 7 symptom scores; rTNSS, reflective total nasal symptom score.



EleCare®

Simple

EleCare® makes meal times the way they should be



Complete, balanced nutrition profiles to support growth and development of infants and children with protein-induced allergies¹⁻⁸

EleCare® PBS INFORMATION: Authority Required. Initial and continuing treatment for cows' milk protein enteropathy in patients up to 24 months of age. Initial and continuing treatment for combined intolerance to cows' milk protein, soy protein and protein hydrolysate formulae, the patient must be older than 24 months of age. Initial and continuing treatment for proven combined immunoglobulin E (IgE) mediated allergy to cows' milk protein and soy protein, the patient must be up to the age of 24 months. Initial and continuing treatment for severe cows' milk protein enteropathy with failure to thrive, the patient must be up to the age of 24 months. EleCare® LCP; Initial treatment: 9339M; Continuing treatment: 9340N. EleCare® Unflavoured and EleCare® Vanilla; initial treatment: 8574G; Continuing treatment: 8575H. See PBS Schedule for full criteria.

Food for Special Medical Purposes. Use under medical supervision. Breast milk is best for babies. Professional advice should be followed before using an infant formula. Introducing partial bottle-feeding could negatively affect breast-feeding. Good maternal nutrition is important for breast-feeding and reversing a decision not to breast-feed may be difficult. Infant formula should be used as directed. Proper use of infant formula is important to the health of the infant. Social and financial implications should be considered when selecting a method of feeding.

References: 1. EleCare® LCP Product Information. 2. EleCare® Unflavoured Product Information. 3. EleCare® Vanilla Product Information. 4. Sicherer SH et al. *J Pediatr* 2001;138(5):688-93. 5. Borschel MW et al. *BMC Pediatrics* 2014;14:136. 6. Borschel MW et al. *Sage Open Medicine* 2014 2(DO): 10.1177/2050312114551857. 7. Liacouras CA et al. *Clin Gastroenterol Hepatol* 2005; 3:1198-206. 8. Borschel MW et al. *Clin Pediatr (Phila)* 2013; 52(10):910-17.

®Registered trade mark of the Abbott Group of Companies. 299 Lane Cove Road, Macquarie Park NSW 2113. ABN 95 000 180 389. Customer Service 1800 225 311. www.abbottnutrition.com.au The Chaos Collective ANANZELE180016b(1)at(1).

life. to the fullest.





Like you, we are dedicated to improving the lives of patients and families with food allergies

We invite you to meet with us at Stand 1



NOVARTIS CORDIALLY INVITES YOU TO ATTEND

Targeted Immune Pathways in Asthma – An Immunology Update

Wednesday 4th September 2019 | 6:30pm – 9:00pm
Karri Room, Parmeila Hilton, 14 Mill St, Perth WA 6000

6:30pm – 7:00pm Arrival and Registration

7:00pm – 8:45pm Presentations and discussion

Currently targeted immune pathways in asthma

Presenter:
Professor Jo Douglass

Emerging pathways of interest in asthma management

Presenter:
Professor Philip Thompson

Panel discussion and Q&A

8:45pm – 9:00pm Closing remarks and meeting close

CHAIR

Dr Li Ping Chung

MBBS(Hons) FRACP, PhD

Respiratory Consultant

Clinical Lead for Airways Disease, Fiona Stanley Hospital

Clinical Lead for Respiratory Multidisciplinary Service, Silver Chain, WA

Clinical Lead, Respiratory Health Network, Department of Health, WA

SPEAKERS

Professor Jo Douglass

BMedSc (Hons), MBBS (Hons) Monash, MD Monash, FRACP

Head, Immunology and Allergy Department, Royal Melbourne Hospital

Clinical Professor, The University of Melbourne

Professor Philip Thompson

MBBS, FRACP, FCCP, MRACMA, FAPSR, FTHORSOC

Director of the Lung Health Clinic

Clinical Professor at The University of WA and Curtin University

Head of the Molecular Genetics and Inflammation Unit,

The Institute of Respiratory Medicine

Consultant Respiratory Physician, Sir Charles Gairdner Hospital

RSVP

Please RSVP to alex.sharpe@novartis.com with the following details:

- 1 Full name
- 2 Practice details
- 3 Dietary requirements (if any)

For any queries, please contact

Naomi Burke

Novartis Respiratory Medical Science Liaison

0416171464

naomi.burke@novartis.com

Note: In line with Medicines Australia Code of Conduct, hospitality, travel or other expenses of any guest, family, or traveling companion will not be paid for or subsidised by Novartis. Attendees are responsible for obtaining approval to receive and/or disclose hospitality as required by their employer or professional association.

Your personal information will be processed in accordance with the Novartis Privacy Policy at <https://www.novartis.com.au/privacy-policy>. Your information, including any information forwarded to the Novartis Patient Safety department, may be processed and stored on servers located in jurisdictions outside of the country in which it was collected.

You consent to Novartis using your personal information to communicate with you about Novartis products and services, and to invite you to, or arrange your participation in, activities managed by Novartis. You are not obliged to provide personal information, however if you do not, you may not be able to participate fully in activities managed by Novartis. You have the right to access, update or correct your personal information or decline to receive marketing communications from Novartis. To find out how, please refer to the Novartis Privacy Policy.

Novartis is committed to Patient Safety. In accordance with regulatory obligations for reporting safety information Novartis processes reports of adverse events experienced by patients on Novartis products when identified by a Novartis representative (or by a third party acting on behalf of Novartis). Novartis Patient Safety may contact you in order to collect further information on the adverse event. This information may be shared with health authorities or other pharmaceutical companies with whom Novartis has a license agreement, and third parties we work with for the purpose of safety reporting. Novartis Pharmaceuticals Australia Pty Limited, ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113, Australia. July 2019. AU-9601. CRD3047.

COMING SOON

APTAMIL ALLERPRO now with SYNEO™



- ✓ Reduces Allergy Symptoms^(1,2)
- ✓ Supports the Immune System⁽³⁻⁷⁾
- ✓ Patented Blend of Prebiotics and Probiotics^(*,†)

BREASTMILK IS BEST FOR BABIES: Professional advice should be followed before using an infant formula. Introducing partial bottle feeding could negatively affect breast feeding. Good maternal nutrition is important for breast feeding and reversing a decision not to breast feed may be difficult. Infant formula should be used as directed. Proper use of an infant formula is important to the health of the infant. Social and financial implications should be considered when selecting a method of feeding.



FOR HEALTHCARE PROFESSIONALS ONLY

* 0.8g/100mL, 90% short chain galacto-oligosaccharides (sc GOS); 10% long chain polyfructose (lc Polyfructose) † Bifidobacterium Breve M16V
References 1. Giampietro PG et al. *Pediatr Allergy Immunol* 2001;12:83-6. 2. Verwimp JM et al. *Eur J Clin Nutr* 1995; 49(1):S39-48. 3. Moro G et al. *Arch Dis Child* 2006; 91:814-819. 4. Arslanoglu S et al. *J Nutr* 2008; 138:1091-1095. 5. van Hoffen E et al. *Allergy* 2009; 64:484-487. 6. Van der Aa, et al. *Clin Exp Allergy*, 2010;40:795-804. 7. Van der Aa, et al. *Allergy*, 2011;66:170-7.

Nutricia Australia Pty Ltd, Level 4, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113 Australia

NUT1019 Aug 2019

Dupixent®

(dupilumab)

now indicated in both atopic dermatitis and asthma¹

Visit us at the Sanofi stand

to learn about Dupixent, which is now indicated for:

ATOPIC DERMATITIS

Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.¹

ASTHMA

Dupixent is indicated as add on maintenance treatment in patients aged 12 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO). Dupixent is indicated as maintenance therapy for oral corticosteroid dependent asthma.¹

PBS Information: This product is not listed on the PBS.

Please review full Product Information before prescribing.

Full Product Information is available from sanofi-aventis australia Pty Ltd at <http://www.guildlink.com.au/gc/ws/sw/pi.cfm?product=swpdupix> or by contacting 1800 818 806.

Dupixent (dupilumab) MINIMUM PRODUCT INFORMATION. INDICATIONS: Atopic dermatitis: Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for chronic systemic therapy. Not indicated for episodic use. **Moderate to severe asthma:** Add on maintenance treatment in patients aged 12 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO). Indicated as maintenance therapy for oral corticosteroid dependent asthma. **DOSAGE AND ADMINISTRATION: Atopic dermatitis:** Initial dose of 600 mg by subcutaneous injection (two 300 mg injections consecutively in different injection sites), followed by 300 mg given every other week. Refer to full PI for preparation, handling and administration. **Moderate to severe asthma:** Initial dose of 400 mg by subcutaneous injection (two 200 mg injections consecutively in different injection sites) followed by 200 mg given every other week. Refer to full PI for preparation, handling and administration. **Oral corticosteroid-dependent asthma or with co-morbid moderate-to-severe atopic dermatitis.** Initial dose of 600 mg by subcutaneous injection (two 300 mg injections consecutively in different injection sites) followed by 300 mg given every other week. **CONTRAINDICATIONS:** Hypersensitivity to dupilumab or any of its excipients. **PRECAUTIONS:** Record the tradename and the batch number to improve traceability, hypersensitivity, helminth infections, conjunctivitis and keratitis, comorbid asthma, concomitant atopic conditions, eosinophilic conditions, acute asthma or deteriorating disease, gradual corticosteroid dose reduction. Refer to full PI. **INTERACTIONS:** Live vaccines, no safety data on co-administration with other immunomodulators. Refer to full PI. **ADVERSE EFFECTS: Atopic dermatitis:** Injection site reactions, conjunctivitis, conjunctivitis allergic, oral herpes, conjunctivitis bacterial, herpes simplex, eosinophilia, eye pruritus, blepharitis, dry eye, hypersensitivity – refer to full PI. **Moderate to severe asthma:** Injection site reactions, oropharyngeal pain, eosinophilia – refer to full PI. **NAME OF SPONSOR:** sanofi-aventis australia Pty Ltd, 12-24 Talavera Road, Macquarie Park, NSW 2113. Date of Preparation: 29 May 2019. Based on Full Product Information with TGA date of approval of 28 May 2019.

References: 1. Australian Approved Product Information for Dupixent, 28 May 2019.

Sanofi and Regeneron are collaborating in a global development program and commercialization for Dupixent (dupilumab). © 2019 Sanofi-Aventis Australia Pty Ltd trading as Sanofi Genzyme – ALL RIGHTS RESERVED.

SANOFI GENZYME

Sanofi-Aventis Australia Pty Ltd trading as Sanofi Genzyme ABN 31 008 558 807. Talavera Corporate Centre. Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. www.sanofi.com.au. Date of preparation July 2019. GZANZ.DUP.19.07.0326. DUP0064.



 Allergen immunotherapy is the closest thing we have to a “cure” for allergies
– Australasian Society of Clinical Immunology and Allergy¹

The 300IR solution in sublingual allergen immunotherapy tablets

Proven post-treatment efficacy²⁻⁶

Early onset of action⁷⁻⁹

Improved symptom control and quality of life^{5,9}

Sublingual immunotherapy tablet for grass pollen allergic rhinitis

Oralair

100 IR & 300 IR or 300 IR sublingual tablets

Sublingual immunotherapy for perennial allergic rhinitis due to house dust mite allergy

Actair

Mixture of American (*D. farinae*) and European (*D. pteronyssinus*) house dust mite allergen extracts

Request your new prescriber starter kit at
allergyaustralia@stallergenesgreer.com

PBS Information: This product is not listed on the PBS.

Please review full product information before prescribing.
Full product information is available on request by calling 1800 824 166.

ACTAIR® Initiation Treatment Sublingual Tablets 100 IR & 300 IR, mixture of American (*D. farinae*) and European (*D. pteronyssinus*) house dust mite allergen extracts. **ACTAIR®** Continuation Treatment Sublingual Tablets 300 IR, mixture of American (*D. farinae*) and European (*D. pteronyssinus*) house dust mite allergen extracts. Excipients include lactose monohydrate. **INDICATIONS** Treatment of house dust mite allergic rhinitis with or without conjunctivitis in adults and adolescents over 12 years diagnosed with house dust mite allergy. **ORALAIR®** Initiation Treatment Sublingual Tablets 100 IR & 300 IR, Allergen pollen extract of 5 grasses. **ORALAIR®** Continuation Treatment Sublingual Tablets 300 IR, allergen pollen extract of 5 grasses. Grass pollen allergen extract from: Rye grass, Timothy, Cocksfoot, Sweet vernal grass, and Meadow grass. Excipients include lactose monohydrate. **INDICATIONS** Treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific IgE to the grass pollen. **CONTRAINDICATIONS** Hypersensitivity to any of the excipients; severe, uncontrolled or unstable asthma; immune deficiency diseases or active forms of auto-immune disorder; malignant diseases; oral inflammations. **PRECAUTIONS** Oral surgery; co-medications that may alter the effects of adrenalin (tricyclic antidepressants, mono amine oxidase inhibitors or beta-adrenergic blockers); rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption; history of eosinophilic esophagitis. For all precautions, refer to full PI. **ADVERSE EFFECTS** Oedema mouth, oral pruritus, ear pruritus, stomatitis, abdominal pain, tongue oedema, lip oedema, oral discomfort, diarrhoea, nausea, paraesthesia oral, dyspepsia, throat irritation, oropharyngeal discomfort, cough, pharyngeal oedema, dyspnoea, nasopharyngitis, gastroenteritis, bronchitis, acute tonsillitis, headache, dermatitis atopic, headache, ear pain, glossitis, oral mucosal blistering, hypoaesthesia oral, gastritis, cheilitis, dry throat, conjunctivitis, pruritus, urticaria [also for ORALAIR®: rhinitis, lacrimation increased, asthma, rhinitis allergic (nasal congestion, sneezing, rhinorrhoea, nasal discomfort) sinus congestion, dysphonia, dry throat, oropharyngeal blistering, tongue pruritus, vomiting]. Patients should be informed of signs and symptoms associated with severe allergic reactions, which occur rarely, and seek immediate medical care if they occur. For all adverse effects, refer to full PI. **DOSE & ADMINISTRATION** First tablet should be taken under medical supervision and the patient monitored for 30 minutes. Tablet must be placed under the tongue until complete disintegration (at least 2 minutes) and then swallowed. Day 1: one 100 IR tablet. Day 2: two 100 IR tablets (placed under tongue simultaneously). Day 3 onwards: one 300 IR tablet per day. Tablet recommended to be taken during the day. For all dose & administration information, refer to full PI [also for ORALAIR®: Treatment should be initiated about 4 months before the pollen season and maintained until the end of the pollen season]. **SPONSOR** Stallergenes Australia Pty Ltd Suite 2408, 4 Daydream St., Warriewood, NSW 2102. Ph: 1800 824 166. Date of preparation: 31st July 2019. **References:** 1. https://www.allergy.org.au/images/pcc/ASCIA_PCC_Allergen_Immunotherapy_2019.pdf, accessed August 2019. 2. Didier A et al. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev. Clin. Immunol. 2014;10(10):1309–1324. 3. ORALAIR® Approved Product Information. 4. ACTAIR® Approved Product Information. 5. Didier A et al. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clin. Transl. 2015;15:12. 6. Bergmann KC, et al. Proven post treatment efficacy. J Allergy Clin Immunol 2014;133:1608-14. 7. Horak F et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J. Allergy Clin. Immunol. 2009;124:471–477. 8. Didier A et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin. Exp. Allergy 2013;43:568–577. 9. Okamoto Y, et al. Allergy 2017;72:435–443.

STALLERGENES  GREER

Stallergenes Australia Pty Ltd t/a Stallergenes Greer. ABN 17 151 366 540. Suite 2408, 4 Daydream St, Warriewood, NSW 2102.
Phone: 1800 824 166. Email: allergyaustralia@stallergenesgreer.com Stallergenes is a registered trademark of Stallergenes SAS. STA060. August 2019.

ASCIA 2020 CONFERENCE

31st ANNUAL CONFERENCE OF THE AUSTRALASIAN SOCIETY OF
CLINICAL IMMUNOLOGY AND ALLERGY (ASCIA)

2-4 September 2020 | Melbourne Convention Centre
South Wharf | Victoria Australia

ASCIA is the peak professional body of clinical immunology
and allergy specialists in Australia and New Zealand.

ASCIA is a member society of the World Allergy Organisation (WAO) and the
Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI).

www.ascia2020.com

ascia

australasian society of clinical immunology and allergy

www.allergy.org.au

Photo: Royal Botanic Gardens Victoria




ascia

australasian society of clinical immunology and allergy

www.ascia2019.com